Prestige Biopharma Ltd

Chart & performance

D1W1MN

P/E

—

P/S

0.01

EPS

—

Div yield, %

—

Shrs. gr., 5y

2.03%

Rev. gr., 5y

-19.89%

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Established in 2015 and based in Singapore, Prestige BioPharma Limited operates as a biopharmaceutical enterprise. The company's activities encompass the research, development, and commercialization of biosimilars and novel antibody therapeutics, primarily targeting the Asia Pacific market. A significant focus for Prestige BioPharma is the creation of antibody-based treatments for critical conditions such as solid tumors, pancreatic cancer, breast cancer, gastric cancer, and arthritis. Furthermore, the firm is also advancing the development of vaccines for the COVID-19 virus.

URL

https://www.prestigebiopharma.com/

IPO date

Feb 05, 2021

Employees

Domiciled in

Incorporated in

Valuation

No data to show